PET Imaging in Preclinical Anti-Aβ Drug Development.
Alzheimer’s disease
Positron Emission Tomography (PET)
amyloid-beta
animal models
drug development
Journal
Pharmaceutical research
ISSN: 1573-904X
Titre abrégé: Pharm Res
Pays: United States
ID NLM: 8406521
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
15
03
2022
accepted:
25
04
2022
pubmed:
3
5
2022
medline:
6
7
2022
entrez:
2
5
2022
Statut:
ppublish
Résumé
Positron emission tomography (PET), a medical imaging technique allowing for studies of the living human brain, has gained an important role in clinical trials of novel drugs against Alzheimer's disease (AD). For example, PET data contributed to the conditional approval in 2021 of aducanumab, an antibody directed towards amyloid-beta (Aβ) aggregates, by showing a dose-dependent reduction in brain amyloid after treatment. In parallel to clinical studies, preclinical studies in animal models of Aβ pathology may also benefit from PET as a tool to detect target engagement and treatment effects of anti-Aβ drug candidates. PET is associated with a high level of translatability between species as similar, non-invasive protocols allow for longitudinal rather than cross-sectional studies and can be used both in a preclinical and clinical setting. This review focuses on the use of preclinical PET imaging in genetically modified animals that express human Aβ, and its present and potential future role in the development of drugs aimed at reducing brain Aβ levels as a therapeutic strategy to halt disease progression in AD.
Identifiants
pubmed: 35501533
doi: 10.1007/s11095-022-03277-z
pii: 10.1007/s11095-022-03277-z
pmc: PMC9246809
doi:
Substances chimiques
Amyloid
0
Amyloid beta-Peptides
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1481-1496Subventions
Organisme : Vetenskapsrådet
ID : 2021-01083
Organisme : Vetenskapsrådet
ID : 2021-03524
Informations de copyright
© 2022. The Author(s).
Références
Gauthier S, Rosa-Neto P, Morais JA, Webster C. World Alzheimer Report 2021: Journey through diagnosis of dementia. London, Englands: Alzheimer's Disease International. 2021.
Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O’Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–6.
pubmed: 27582220
doi: 10.1038/nature19323
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study G. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–41.
doi: 10.1056/NEJMoa013128
Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14(2):135–46.
pubmed: 10885864
doi: 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0
Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.
pubmed: 1566067
doi: 10.1126/science.1566067
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595–608.
pubmed: 27025652
pmcid: 4888851
doi: 10.15252/emmm.201606210
Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106(10):4012–7.
pubmed: 19228947
pmcid: 2656196
doi: 10.1073/pnas.0811698106
Tucker S, Moller C, Tegerstedt K, Lord A, Laudon H, Sjodahl J, Soderberg L, Spens E, Sahlin C, Waara ER, Satlin A, Gellerfors P, Osswald G, Lannfelt L. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575–88.
pubmed: 25096615
doi: 10.3233/JAD-140741
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6(8):916–9.
pubmed: 10932230
doi: 10.1038/78682
Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, Soderberg L, Moller C, Gellerfors P, Lannfelt L, Pettersson FE, Nilsson LN. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s disease. Neurobiol Dis. 2009;36(3):425–34.
pubmed: 19703562
doi: 10.1016/j.nbd.2009.08.007
Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19.
pubmed: 14991808
doi: 10.1002/ana.20009
Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–372.
Swanson JD, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;17(11):80.
doi: 10.1186/s13195-021-00813-8
Waldron AM, Verhaeghe J, wyffels L, Schmidt M, Langlois X, Van Der Linden A, Stroobants S, Staelens S. Preclinical Comparison of the Amyloid-beta Radioligands [(11)C]Pittsburgh compound B and [(18)F]florbetaben in Aged APPPS1–21 and BRI1–42 Mouse Models of Cerebral Amyloidosis. Mol Imaging Biol. 2015;17(5):688–696.
Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, Chan JG, Young K, Tochon-Danguy H, Masters CL, Rowe CC. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983–9.
pubmed: 22398958
doi: 10.1007/s00259-012-2088-x
Rojas S, Herance JR, Gispert JD, Abad S, Torrent E, Jimenez X, Pareto D, Perpina U, Sarroca S, Rodriguez E, Ortega-Aznar A, Sanfeliu C. In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography. Neurobiol Aging. 2013;34(7):1790–8.
pubmed: 23402900
doi: 10.1016/j.neurobiolaging.2012.12.027
Snellman A, Lopez-Picon FR, Rokka J, Salmona M, Forloni G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease. J Nucl Med. 2013;54(8):1434–41.
pubmed: 23833271
doi: 10.2967/jnumed.112.110163
Snellman A, Rokka J, Lopez-Picon FR, Eskola O, Salmona M, Forloni G, Scheinin M, Solin O, Rinne JO, Haaparanta-Solin M. In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer’s disease with a high specific activity PET imaging agent [(18)F]flutemetamol. EJNMMI Res. 2014;4:37.
pubmed: 25977876
pmcid: 4412375
doi: 10.1186/s13550-014-0037-3
Waldron AM, Wintmolders C, Bottelbergs A, Kelley JB, Schmidt ME, Stroobants S, Langlois X, Staelens S. In vivo molecular neuroimaging of glucose utilization and its association with fibrillar amyloid-beta load in aged APPPS1-21 mice. Alzheimers Res Ther. 2015;7(1):76.
pubmed: 26666747
pmcid: 4678474
doi: 10.1186/s13195-015-0158-6
Meier SR, Sehlin D, Roshanbin S, Falk VL, Saito T, Saido TC, Neumann U, Rokka J, Eriksson J, Syvanen S. (11)C-PiB and (124)I-Antibody PET Provide Differing Estimates of Brain Amyloid-beta After Therapeutic Intervention. J Nucl Med. 2022;63(2):302–9.
pubmed: 34088777
pmcid: 8805773
doi: 10.2967/jnumed.121.262083
Sacher C, Blume T, Beyer L, Peters F, Eckenweber F, Sgobio C, Deussing M, Albert NL, Unterrainer M, Lindner S, Gildehaus FJ, von Ungern-Sternberg B, Brzak I, Neumann U, Saito T, Saido TC, Bartenstein P, Rominger A, Herms J, Brendel M. Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second-Generation Amyloid-beta Mouse Model. J Nucl Med. 2019;60(12):1787–93.
pubmed: 31302633
pmcid: 6894380
doi: 10.2967/jnumed.119.227322
Waldron AM, Fissers J, Van Eetveldt A, Van Broeck B, Mercken M, Pemberton DJ, Van Der Veken P, Augustyns K, Joossens J, Stroobants S, Dedeurwaerdere S, Wyffels L, Staelens S. In Vivo Amyloid-beta Imaging in the APPPS1-21 Transgenic Mouse Model with a (89)Zr-Labeled Monoclonal Antibody. Front Aging Neurosci. 2016;8:67.
pubmed: 27064204
pmcid: 4815004
doi: 10.3389/fnagi.2016.00067
Fissers J, Waldron AM, De Vijlder T, Van Broeck B, Pemberton DJ, Mercken M, Van Der Veken P, Joossens J, Augustyns K, Dedeurwaerdere S, Stroobants S, Staelens S, Wyffels L. Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-beta Deposition in the Brain. Mol Imaging Biol. 2016;18(4):598–605.
pubmed: 26846128
doi: 10.1007/s11307-016-0935-z
Syvanen S, Eden D, Sehlin D. Cationization increases brain distribution of an amyloid-beta protofibril selective F(ab’)2 fragment. Biochem Biophys Res Commun. 2017;493(1):120–5.
pubmed: 28919420
doi: 10.1016/j.bbrc.2017.09.065
Magnusson K, Sehlin D, Syvanen S, Svedberg MM, Philipson O, Soderberg L, Tegerstedt K, Holmquist M, Gellerfors P, Tolmachev V, Antoni G, Lannfelt L, Hall H, Nilsson LN. Specific uptake of an amyloid-beta protofibril-binding antibody-tracer in AbetaPP transgenic mouse brain. J Alzheimers Dis. 2013;37(1):29–40.
pubmed: 23780660
doi: 10.3233/JAD-130029
Hultqvist G, Syvanen S, Fang XT, Lannfelt L, Sehlin D. Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor. Theranostics. 2017;7(2):308–18.
pubmed: 28042336
pmcid: 5197066
doi: 10.7150/thno.17155
Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R, Kim DJ, Srivastava A, Bedard C, Henne KR, Giese T, Assimon VA, Chen X, Zhang Y, Solanoy H, Jenkins K, Sanchez PE, Kane L, Miyamoto T, Chew KS, Pizzo ME, Liang N, Calvert MEK, DeVos SL, Baskaran S, Hall S, Sweeney ZK, Thorne RG, Watts RJ, Dennis MS, Silverman AP, Zuchero YJY. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. 2020;12(545).
Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, Loetscher H, Ghosh A, Freskgard PO. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81(1):49–60.
pubmed: 24411731
doi: 10.1016/j.neuron.2013.10.061
Pardridge WM. Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies. Expert Opin Biol Ther. 2016;16(12):1455–68.
pubmed: 27572805
doi: 10.1080/14712598.2016.1230195
Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3(84):84ra44.
Rofo F, Ugur Yilmaz C, Metzendorf N, Gustavsson T, Beretta C, Erlandsson A, Sehlin D, Syvanen S, Nilsson P, Hultqvist G. Enhanced neprilysin-mediated degradation of hippocampal Abeta42 with a somatostatin peptide that enters the brain. Theranostics. 2021;11(2):789–804.
pubmed: 33391505
pmcid: 7738863
doi: 10.7150/thno.50263
Fang XT, Sehlin D, Lannfelt L, Syvanen S, Hultqvist G. Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells. Biol Proced Online. 2017;19:11.
pubmed: 28932173
pmcid: 5603040
doi: 10.1186/s12575-017-0060-7
Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103(1):334–45.
pubmed: 17623042
Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial I. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061–2070.
Fang XT, Hultqvist G, Meier SR, Antoni G, Sehlin D, Syvanen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. Neuroimage. 2019;184:881–8.
pubmed: 30300753
doi: 10.1016/j.neuroimage.2018.10.011
Sehlin D, Fang XT, Cato L, Antoni G, Lannfelt L, Syvanen S. Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease. Nat Commun. 2016;7:10759.
pubmed: 26892305
pmcid: 4762893
doi: 10.1038/ncomms10759
Sehlin D, Fang XT, Meier SR, Jansson M, Syvanen S. Pharmacokinetics, biodistribution and brain retention of a bispecific antibody-based PET radioligand for imaging of amyloid-beta. Sci Rep. 2017;7(1):17254.
pubmed: 29222502
pmcid: 5722892
doi: 10.1038/s41598-017-17358-2
Stocki P, Szary JM, Jacobsen CL, Demydchuk M, Northall L, Moos T, Walsh FS, Rutkowski JL. High efficiency blood-brain barrier transport using a VNAR targeting the Transferrin Receptor 1 (TfR1). bioRxiv. 2019:816900.
Zysk M, Clausen F, Aguilar X, Sehlin D, Syvanen S, Erlandsson A. Long-Term Effects of Traumatic Brain Injury in a Mouse Model of Alzheimer’s Disease. J Alzheimers Dis. 2019;72(1):161–80.
pubmed: 31561367
pmcid: 6839469
doi: 10.3233/JAD-190572
Meier SR, Syvanen S, Hultqvist G, Fang XT, Roshanbin S, Lannfelt L, Neumann U, Sehlin D. Antibody-Based In Vivo PET Imaging Detects Amyloid-beta Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition. J Nucl Med. 2018;59(12):1885–91.
pubmed: 29853653
pmcid: 6278900
doi: 10.2967/jnumed.118.213140
Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ, Amyloid PETSG, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sanchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chetelat G, Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939–1949.
Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab. 2001;21(6):635–52.
pubmed: 11488533
doi: 10.1097/00004647-200106000-00002
Xiong M, Roshanbin S, Rokka J, Schlein E, Ingelsson M, Sehlin D, Eriksson J, Syvanen S. In vivo imaging of synaptic density with [(11)C]UCB-J PET in two mouse models of neurodegenerative disease. Neuroimage. 2021;239: 118302.
pubmed: 34174391
doi: 10.1016/j.neuroimage.2021.118302
Verhaeghe J, Bertoglio D, Kosten L, Thomae D, Verhoye M, Van Der Linden A, Wyffels L, Stroobants S, Wityak J, Dominguez C, Mrzljak L, Staelens S. Noninvasive Relative Quantification of [(11)C]ABP688 PET Imaging in Mice Versus an Input Function Measured Over an Arteriovenous Shunt. Front Neurol. 2018;9:516.
pubmed: 30013509
pmcid: 6036254
doi: 10.3389/fneur.2018.00516
Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, Debnath ML, Holt DP, Huang GF, Shao L, DeKosky ST, Price JC, Mathis CA. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer’s disease brain but not in transgenic mouse brain. J Neurosci. 2005;25(46):10598–606.
pubmed: 16291932
pmcid: 6725842
doi: 10.1523/JNEUROSCI.2990-05.2005
Toyama H, Ye D, Ichise M, Liow JS, Cai L, Jacobowitz D, Musachio JL, Hong J, Crescenzo M, Tipre D, Lu JQ, Zoghbi S, Vines DC, Seidel J, Katada K, Green MV, Pike VW, Cohen RM, Innis RB. PET imaging of brain with the beta-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2005;32(5):593–600.
pubmed: 15791432
doi: 10.1007/s00259-005-1780-5
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274(5284):99–102.
pubmed: 8810256
doi: 10.1126/science.274.5284.99
Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A. 1997;94(24):13287–92.
pubmed: 9371838
pmcid: 24301
doi: 10.1073/pnas.94.24.13287
Maeda J, Ji B, Irie T, Tomiyama T, Maruyama M, Okauchi T, Staufenbiel M, Iwata N, Ono M, Saido TC, Suzuki K, Mori H, Higuchi M, Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer’s disease enabled by positron emission tomography. J Neurosci. 2007;27(41):10957–68.
pubmed: 17928437
pmcid: 6672864
doi: 10.1523/JNEUROSCI.0673-07.2007
Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci. 2003;23(26):8989–9003.
pubmed: 14523101
pmcid: 6740398
doi: 10.1523/JNEUROSCI.23-26-08989.2003
Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN. The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging. 2006;27(1):67–77.
pubmed: 16298242
doi: 10.1016/j.neurobiolaging.2004.12.007
Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006;26(40):10129–40.
pubmed: 17021169
pmcid: 6674618
doi: 10.1523/JNEUROSCI.1202-06.2006
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39(3):409–21.
pubmed: 12895417
doi: 10.1016/S0896-6273(03)00434-3
Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Holscher C, Mathews PM, Jucker M. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7(9):940–6.
pubmed: 16906128
pmcid: 1559665
doi: 10.1038/sj.embor.7400784
Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng. 2001;17(6):157–65.
pubmed: 11337275
doi: 10.1016/S1389-0344(01)00067-3
Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single App knock-in mouse models of Alzheimer’s disease. Nat Neurosci. 2014;17(5):661–3.
pubmed: 24728269
doi: 10.1038/nn.3697
Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313(5794):1781–4.
pubmed: 16990547
doi: 10.1126/science.1131864
Chaney AM, Lopez-Picon FR, Serriere S, Wang R, Bochicchio D, Webb SD, Vandesquille M, Harte MK, Georgiadou C, Lawrence C, Busson J, Vercouillie J, Tauber C, Buron F, Routier S, Reekie T, Snellman A, Kassiou M, Rokka J, Davies KE, Rinne JO, Salih DA, Edwards FA, Orton LD, Williams SR, Chalon S, Boutin H. Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. Theranostics. 2021;11(14):6644–67.
pubmed: 34093845
pmcid: 8171096
doi: 10.7150/thno.56059
Kang MS, Aliaga AA, Shin M, Mathotaarachchi S, Benedet AL, Pascoal TA, Therriault J, Chamoun M, Savard M, Devenyi GA, Mathieu A, Chakravarty MM, Sandelius A, Blennow K, Zetterberg H, Soucy JP, Cuello AC, Massarweh G, Gauthier S, Rosa-Neto P, Alzheimer's Disease Neuroimaging I. Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. Mol Psychiatry. 2021;26(10):5989–6001.
Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC. A novel transgenic rat model with a full Alzheimer’s-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis. 2010;20(1):113–26.
pubmed: 20164597
doi: 10.3233/JAD-2010-1349
Cohen RM, Rezai-Zadeh K, Weitz TM, Rentsendorj A, Gate D, Spivak I, Bholat Y, Vasilevko V, Glabe CG, Breunig JJ, Rakic P, Davtyan H, Agadjanyan MG, Kepe V, Barrio JR, Bannykh S, Szekely CA, Pechnick RN, Town T. A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric abeta, and frank neuronal loss. J Neurosci. 2013;33(15):6245–56.
pubmed: 23575824
pmcid: 3720142
doi: 10.1523/JNEUROSCI.3672-12.2013
Tournier BB, Tsartsalis S, Ceyzeriat K, Fraser BH, Gregoire MC, Kovari E, Millet P. Astrocytic TSPO Upregulation Appears Before Microglial TSPO in Alzheimer’s Disease. J Alzheimers Dis. 2020;77(3):1043–56.
pubmed: 32804124
pmcid: 7683091
doi: 10.3233/JAD-200136
Filip T, Mairinger S, Neddens J, Sauberer M, Flunkert S, Stanek J, Wanek T, Okamura N, Langer O, Hutter-Paier B, Kuntner C. Characterization of an APP/tau rat model of Alzheimer’s disease by positron emission tomography and immunofluorescent labeling. Alzheimers Res Ther. 2021;13(1):175.
pubmed: 34656177
pmcid: 8522096
doi: 10.1186/s13195-021-00916-2
Parent MJ, Zimmer ER, Shin M, Kang MS, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Do Carmo S, Dea D, Poirier J, Soucy JP, Gauthier S, Cuello AC, Rosa-Neto P. Multimodal Imaging in Rat Model Recapitulates Alzheimer’s Disease Biomarkers Abnormalities. J Neurosci. 2017;37(50):12263–71.
pubmed: 29097597
pmcid: 5729194
doi: 10.1523/JNEUROSCI.1346-17.2017
Finnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, Dhaher R, Matuskey D, Baum E, Holden D, Spencer DD, Mercier J, Hannestad J, Huang Y, Carson RE. Imaging synaptic density in the living human brain. Sci Transl Med. 2016;8(348):348ra396.
Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34(2):457–68.
pubmed: 23234879
doi: 10.3233/JAD-122059
Villemagne VL, Furumoto S, Fodero-Tavoletti MT, Mulligan RS, Hodges J, Harada R, Yates P, Piguet O, Pejoska S, Dore V, Yanai K, Masters CL, Kudo Y, Rowe CC, Okamura N. In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2014;41(5):816–26.
pubmed: 24514874
doi: 10.1007/s00259-013-2681-7
Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6):1094–108.
pubmed: 24050400
doi: 10.1016/j.neuron.2013.07.037
Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P. Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther. 2017;9(1):25.
pubmed: 28359327
pmcid: 5374697
doi: 10.1186/s13195-017-0253-y
Pilebro B, Arvidsson S, Lindqvist P, Sundstrom T, Westermark P, Antoni G, Suhr O, Sorensen J. Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR). J Nucl Cardiol. 2018;25(1):240–8.
pubmed: 27645889
doi: 10.1007/s12350-016-0638-5
Roshanbin S, Xiong M, Hultqvist G, Soderberg L, Zachrisson O, Meier S, Ekmark-Lewen S, Bergstrom J, Ingelsson M, Sehlin D, Syvanen S. In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology. 2022;208: 108985.
pubmed: 35149134
doi: 10.1016/j.neuropharm.2022.108985
Scholl M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Langstrom B, Almkvist O, Graff C, Nordberg A. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology. 2012;79(3):229–36.
pubmed: 22700814
doi: 10.1212/WNL.0b013e31825fdf18
Abrahamson EE, Kofler JK, Becker CR, Price JC, Newell KL, Ghetti B, Murrell JR, McLean CA, Lopez OL, Mathis CA, Klunk WE, Villemagne VL, Ikonomovic MD. 11C-PiB PET can underestimate brain amyloid-beta burden when cotton wool plaques are numerous. Brain. 2021.
Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P, Selkoe DJ. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med. 1997;3(1):67–72.
Michno W, Wehrli P, Meier SR, Sehlin D, Syvanen S, Zetterberg H, Blennow K, Hanrieder J. Chemical imaging of evolving amyloid plaque pathology and associated Abeta peptide aggregation in a transgenic mouse model of Alzheimer’s disease. J Neurochem. 2020;152(5):602–16.
pubmed: 31605538
doi: 10.1111/jnc.14888
Manook A, Yousefi BH, Willuweit A, Platzer S, Reder S, Voss A, Huisman M, Settles M, Neff F, Velden J, Schoor M, von der Kammer H, Wester HJ, Schwaiger M, Henriksen G, Drzezga A. Small-animal PET imaging of amyloid-beta plaques with [11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer’s disease. PLoS ONE. 2012;7(3): e31310.
pubmed: 22427802
pmcid: 3302888
doi: 10.1371/journal.pone.0031310
Brendel M, Jaworska A, Griessinger E, Rotzer C, Burgold S, Gildehaus FJ, Carlsen J, Cumming P, Baumann K, Haass C, Steiner H, Bartenstein P, Herms J, Rominger A. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models. PLoS ONE. 2015;10(2): e0116678.
pubmed: 25706990
pmcid: 4338066
doi: 10.1371/journal.pone.0116678
Poisnel G, Dhilly M, Moustie O, Delamare J, Abbas A, Guilloteau D, Barre L. PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol Aging. 2012;33(11):2561–71.
pubmed: 22277262
doi: 10.1016/j.neurobiolaging.2011.12.024
Sacher C, Blume T, Beyer L, Biechele G, Sauerbeck J, Eckenweber F, Deussing M, Focke C, Parhizkar S, Lindner S, Gildehaus FJ, von Ungern-Sternberg B, Baumann K, Tahirovic S, Kleinberger G, Willem M, Haass C, Bartenstein P, Cumming P, Rominger A, Herms J, Brendel M. Asymmetry of Fibrillar Plaque Burden in Amyloid Mouse Models. J Nucl Med. 2020;61(12):1825–31.
pubmed: 32414948
doi: 10.2967/jnumed.120.242750
Rominger A, Brendel M, Burgold S, Keppler K, Baumann K, Xiong G, Mille E, Gildehaus FJ, Carlsen J, Schlichtiger J, Niedermoser S, Wangler B, Cumming P, Steiner H, Herms J, Haass C, Bartenstein P. Longitudinal assessment of cerebral beta-amyloid deposition in mice overexpressing Swedish mutant beta-amyloid precursor protein using 18F-florbetaben PET. J Nucl Med. 2013;54(7):1127–34.
pubmed: 23729696
doi: 10.2967/jnumed.112.114660
Biechele G, Monasor LS, Wind K, Blume T, Parhizkar S, Arzberger T, Sacher C, Beyer L, Eckenweber F, Gildehaus FJ, von Ungern-Sternberg B, Willem M, Bartenstein P, Cumming P, Rominger A, Herms J, Lichtenthaler SF, Haass C, Tahirovic S, Brendel M. Glitter in the Darkness? Nonfibrillar beta-Amyloid Plaque Components Significantly Impact the beta-Amyloid PET Signal in Mouse Models of Alzheimer Disease. J Nucl Med. 2022;63(1):117–24.
pubmed: 34016733
doi: 10.2967/jnumed.120.261858
Brendel M, Jaworska A, Herms J, Trambauer J, Rotzer C, Gildehaus FJ, Carlsen J, Cumming P, Bylund J, Luebbers T, Bartenstein P, Steiner H, Haass C, Baumann K, Rominger A. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic gamma-secretase modulator treatment. Mol Psychiatry. 2015;20(10):1179–87.
pubmed: 26055427
pmcid: 4759098
doi: 10.1038/mp.2015.74
Brendel M, Jaworska A, Overhoff F, Blume T, Probst F, Gildehaus FJ, Bartenstein P, Haass C, Bohrmann B, Herms J, Willem M, Rominger A. Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Abeta deposition rate and plaque burden at treatment initiation. Theranostics. 2018;8(18):4957–68.
pubmed: 30429879
pmcid: 6217065
doi: 10.7150/thno.27868
Deleye S, Waldron AM, Verhaeghe J, Bottelbergs A, Wyffels L, Van Broeck B, Langlois X, Schmidt M, Stroobants S, Staelens S. Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease. J Nucl Med. 2017;58(12):1977–83.
pubmed: 28611242
doi: 10.2967/jnumed.116.187625
Snellman A, Rokka J, Lopez-Picon FR, Helin S, Re F, Loyttyniemi E, Pihlaja R, Forloni G, Salmona M, Masserini M, Solin O, Rinne JO, Haaparanta-Solin M. Applicability of [(11)C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model. Neurobiol Aging. 2017;57:84–94.
pubmed: 28605642
doi: 10.1016/j.neurobiolaging.2017.05.008
Syvanen S, Hultqvist G, Gustavsson T, Gumucio A, Laudon H, Soderberg L, Ingelsson M, Lannfelt L, Sehlin D. Efficient clearance of Abeta protofibrils in AbetaPP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimers Res Ther. 2018;10(1):49.
pubmed: 29793530
pmcid: 5968497
doi: 10.1186/s13195-018-0377-8
Gustavsson T, Syvanen S, O’Callaghan P, Sehlin D. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-beta antibody in a mouse model of Alzheimer’s disease. Transl Neurodegener. 2020;9(1):37.
pubmed: 32951598
pmcid: 7504681
doi: 10.1186/s40035-020-00214-1
Gustafsson S, Gustavsson T, Roshanbin S, Hultqvist G, Hammarlund-Udenaes M, Sehlin D, Syvanen S. Blood-brain barrier integrity in a mouse model of Alzheimer’s disease with or without acute 3D6 immunotherapy. Neuropharmacology. 2018;143:1–9.
pubmed: 30201212
doi: 10.1016/j.neuropharm.2018.09.001
Jureus A, Swahn BM, Sandell J, Jeppsson F, Johnson AE, Johnstrom P, Neelissen JA, Sunnemark D, Farde L, Svensson SP. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem. 2010;114(3):784–94.
pubmed: 20477945
doi: 10.1111/j.1471-4159.2010.06812.x
Rowe CC, Pejoska S, Mulligan RS, Jones G, Chan JG, Svensson S, Cselenyi Z, Masters CL, Villemagne VL. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for beta-amyloid imaging in aging and dementia. J Nucl Med. 2013;54(6):880–6.
pubmed: 23575995
doi: 10.2967/jnumed.112.114785
Sehlin D, Syvanen S. Engineered antibodies: new possibilities for brain PET? Eur J Nucl Med Mol Imaging. 2019;46(13):2848–58.
pubmed: 31342134
pmcid: 6879437
doi: 10.1007/s00259-019-04426-0
Faresjo R, Bonvicini G, Fang XT, Aguilar X, Sehlin D, Syvanen S. Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size. Fluids Barriers CNS. 2021;18(1):26.
pubmed: 34078410
pmcid: 8170802
doi: 10.1186/s12987-021-00257-0
Syvanen S, Fang XT, Hultqvist G, Meier SR, Lannfelt L, Sehlin D. A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils - a new concept for neuroimaging. Neuroimage. 2017;148:55–63.
pubmed: 28069541
doi: 10.1016/j.neuroimage.2017.01.004
Syvanen S, Fang XT, Faresjo R, Rokka J, Lannfelt L, Olberg DE, Eriksson J, Sehlin D. Fluorine-18-Labeled Antibody Ligands for PET Imaging of Amyloid-beta in Brain. ACS Chem Neurosci. 2020;11(24):4460–8.
pubmed: 33236886
doi: 10.1021/acschemneuro.0c00652
Calvo-Rodriguez M, Hou SS, Snyder AC, Dujardin S, Shirani H, Nilsson KPR, Bacskai BJ. In vivo detection of tau fibrils and amyloid beta aggregates with luminescent conjugated oligothiophenes and multiphoton microscopy. Acta Neuropathol Commun. 2019;7(1):171.
pubmed: 31703739
pmcid: 6839235
doi: 10.1186/s40478-019-0832-1
Klingstedt T, Nilsson KP. Luminescent conjugated poly- and oligo-thiophenes: optical ligands for spectral assignment of a plethora of protein aggregates. Biochem Soc Trans. 2012;40(4):704–10.
pubmed: 22817720
doi: 10.1042/BST20120009
Snellman A, Takkinen JS, Lopez-Picon FR, Eskola O, Solin O, Rinne JO, Haaparanta-Solin M. Effect of genotype and age on cerebral [(18)F]FDG uptake varies between transgenic APPSwe-PS1dE9 and Tg2576 mouse models of Alzheimer’s disease. Sci Rep. 2019;9(1):5700.
pubmed: 30952945
pmcid: 6450965
doi: 10.1038/s41598-019-42074-4
Kuntner C, Kesner AL, Bauer M, Kremslehner R, Wanek T, Mandler M, Karch R, Stanek J, Wolf T, Muller M, Langer O. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer’s disease. Mol Imaging Biol. 2009;11(4):236–40.
pubmed: 19214638
doi: 10.1007/s11307-009-0198-z
Waldron AM, Wyffels L, Verhaeghe J, Richardson JC, Schmidt M, Stroobants S, Langlois X, Staelens S. Longitudinal Characterization of [18F]-FDG and [18F]-AV45 Uptake in the Double Transgenic TASTPM Mouse Model. J Alzheimers Dis. 2017;55(4):1537–48.
pubmed: 27911309
doi: 10.3233/JAD-160760
Brendel M, Probst F, Jaworska A, Overhoff F, Korzhova V, Albert NL, Beck R, Lindner S, Gildehaus FJ, Baumann K, Bartenstein P, Kleinberger G, Haass C, Herms J, Rominger A. Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study. J Nucl Med. 2016;57(6):954–60.
pubmed: 26912428
doi: 10.2967/jnumed.115.167858
Vivash L, O’Brien TJ. Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases? J Nucl Med. 2016;57(2):165–8.
pubmed: 26697963
doi: 10.2967/jnumed.114.141713
Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, Albert NL, Carlsen J, Lindner S, Gildehaus FJ, Ozmen L, Suarez-Calvet M, Bartenstein P, Baumann K, Ewers M, Herms J, Haass C, Rominger A. Increase of TREM2 during Aging of an Alzheimer’s Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. Front Aging Neurosci. 2017;9:8.
pubmed: 28197095
pmcid: 5282474
doi: 10.3389/fnagi.2017.00008
Focke C, Blume T, Zott B, Shi Y, Deussing M, Peters F, Schmidt C, Kleinberger G, Lindner S, Gildehaus FJ, Beyer L, von Ungern-Sternberg B, Bartenstein P, Ozmen L, Baumann K, Dorostkar MM, Haass C, Adelsberger H, Herms J, Rominger A, Brendel M. Early and Longitudinal Microglial Activation but Not Amyloid Accumulation Predicts Cognitive Outcome in PS2APP Mice. J Nucl Med. 2019;60(4):548–54.
pubmed: 30262517
doi: 10.2967/jnumed.118.217703
Olsen M, Aguilar X, Sehlin D, Fang XT, Antoni G, Erlandsson A, Syvanen S. Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer’s Disease. Mol Imaging Biol. 2018;20(4):605–14.
pubmed: 29297157
doi: 10.1007/s11307-017-1153-z
Rodriguez-Vieitez E, Ni R, Gulyas B, Toth M, Haggkvist J, Halldin C, Voytenko L, Marutle A, Nordberg A. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. Eur J Nucl Med Mol Imaging. 2015;42(7):1119–32.
pubmed: 25893384
pmcid: 4424277
doi: 10.1007/s00259-015-3047-0
Jay TR, von Saucken VE, Landreth GE. TREM2 in Neurodegenerative Diseases. Mol Neurodegener. 2017;12(1):56.
pubmed: 28768545
pmcid: 5541421
doi: 10.1186/s13024-017-0197-5
Meier SR, Sehlin D, Hultqvist G, Syvanen S. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer's Disease. Mol Imaging Biol. 2021.
Sadasivam P, Fang XT, Toyonaga T, Lee S, Xu Y, Zheng MQ, Spurrier J, Huang Y, Strittmatter SM, Carson RE, Cai Z. Quantification of SV2A Binding in Rodent Brain Using [(18)F]SynVesT-1 and PET Imaging. Mol Imaging Biol. 2021;23(3):372–81.
pubmed: 33258040
doi: 10.1007/s11307-020-01567-9
Toyonaga T, Smith LM, Finnema SJ, Gallezot JD, Naganawa M, Bini J, Mulnix T, Cai Z, Ropchan J, Huang Y, Strittmatter SM, Carson RE. In Vivo Synaptic Density Imaging with (11)C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. J Nucl Med. 2019;60(12):1780–6.
pubmed: 31101744
pmcid: 6894376
doi: 10.2967/jnumed.118.223867